이대용 (Virginia Tech) | 한빛사논문 > 한빛사

한빛사논문

조회278

Virginia Tech

CV File

Nat. Cancer, Published: 07 August 2025 | https://doi.org/10.1038/s43018-025-01025-x Nanotechnology for immuno-oncology

Adam J. Grippin^1,6, DaeYong Lee^2.3,6, Eileen E. Parkes⁴, Wen Jiang^1* & Betty Y. S. Kim^5*

¹Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
²Fralin Biomedical Research Institute at VTC, Virginia Tech, Roanoke, VA, USA
³Department of Biomedical Engineering, Virginia Tech, Blacksburg, VA, USA
⁴Department of Oncology, Oxford University, Oxford, UK
⁵Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
⁶These authors contributed equally: Adam J. Grippin, DaeYong Lee.

*Corresponding authors
Correspondence to Wen Jiang or Betty Y. S. Kim.

Abstract

Although the first generation of cancer immunotherapeutics produced unprecedented improvements in clinical outcomes for individuals with cancer, novel strategies to increase treatment specificity, delivery efficiency and pharmacokinetics are still needed. In this Review, we describe the potential advantages and current limitations of nanomaterials for cancer immunotherapy and highlight rational uses of nanosystems to generate potent and durable antitumor immune responses. We close with a review of the current state of clinical development of nanomedicine for cancer immunotherapy.

논문정보